Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28502920 | 0.98 | CYP2A6 (0.48) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL9729982 | 0.76 | CYP2A6 (0.42) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL4381193 | 0.74 | CYP2A6 (0.54) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL4067824 | 0.73 | CYP2A6 (0.40) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL264791 | 0.72 | CYP2A6 (0.52) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL6836543 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL1308770 | 0.70 | CYP2A6 (0.54) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL4807204 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL546825 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL1568025 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247837-A1 | NEW CYCLIC COMPOUNDS, PROCESS FOR THE PRODUCTION THEREOF, AND USE OF SAID CYCLIC COMPOUNDS IN COSMETIC PREPARATIONS | Eberhard-Karls-Universität Tübingen (DE) | 2023-09-27 | — | — | EP | claimed |
| CN-116635400-A | Novel cyclic compounds, method for the production thereof and use of these cyclic compounds in cosmetic preparations | 艾伯哈特卡尔斯图宾根大学 | 2023-08-22 | — | — | CN | claimed |
| CN-116134016-A | Tricyclic heterocycles | 默克专利股份公司 | 2023-05-16 | — | — | CN | claimed |
| CN-115515959-A | Tricyclic heterocycles as TEAD binders | 默克专利股份公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2022106667-A1 | NEW CYCLIC COMPOUNDS, PROCESS FOR THE PRODUCTION THEREOF, AND USE OF SAID CYCLIC COMPOUNDS IN COSMETIC PREPARATIONS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2022-05-27 | — | — | WO | claimed |
| EP-4001296-A1 | NOVEL CYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN COSMETIC COMPOSITIONS | Eberhard Karls Universität Tübingen (DE) | 2022-05-25 | — | — | EP | claimed |
| US-10550112-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | claimed |
| US-20180194758-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | claimed |
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | claimed |
| EP-3325469-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| US-5169841-A | Enzyme inhibitors, hypotensive agents, high enteral bioauailability | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | claimed |
| US-5104869-A | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1992-04-14 | — | — | US | claimed |
| EP-0460679-A2 | Endothelin antagonistic peptide derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-12-11 | — | — | EP | claimed |
| EP-0435059-A1 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-07-03 | — | — | EP | claimed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | claimed |
| EP-0427939-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0371467-A2 | Beta-amino boron acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-06 | — | — | EP | claimed |
| EP-0354522-A1 | Use of alpha-aminoboronic acid derivatives in prevention and treatement of viral diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-02-14 | — | — | EP | claimed |
| EP-0315574-A2 | Renin inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-10 | — | — | EP | claimed |
| EP-0050072-B1 | CYCLOPROPYL METHYL PIPERAZINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS | INNOTHERA (FR) | 1984-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550112-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | CYP2A6 3294/4885MAPT 2402/4885HDAC3 3859/4885 |
| US-20180194758-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | CYP2A6 3635/4885MAPT 2836/4885HDAC3 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.